Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameAb&b Bio-Tech-B
Stock Code02627
Company Full NameAb&B Bio-Tech Co., Ltd.
IndustryBiotech & Pharma
Principal Activitiesindustry veteran with over 15 years of experience in the biotechnology and pharmaceutical industries
Listing Date2025-08-11
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterChapter 18A
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 江蘇省泰州市 醫藥高新區 杏林路32號
Business Address (Hong Kong)248 Queen’s Road East Wanchai Hong Kong
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.abbbio.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism B
Offer PriceHK$ 12.90 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 2,580
Par ValueRMB 1.0 / shares
Offer Period2025-07-31 to 2025-08-05
Global Offering Shares33,442,600 shares
HK Public Offer Shares (Initial)3,344,260 shares (10.0%)
Public Offer Lots (Initial)16,721lots (Pool A8,360lots,Pool B8,361lots)
International Placing Shares (Initial)30,098,340 shares (90.0%)
Offer Ratio~8.5%
Total Shares Post-IPO393,442,600 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)中信证券(香港)有限公司 CE AAK249
Cornerstone Share21.3%
Clawback TiersMechanism B: no clawback
Reallocation OptionNo
Total Global Offering SizeHK$ 431,409,540

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 2,580
2 lots 400 HK$ 5,160
3 lots 600 HK$ 7,740
4 lots 800 HK$ 10,320
5 lots 1,000 HK$ 12,900
6 lots 1,200 HK$ 15,480
7 lots 1,400 HK$ 18,060
8 lots 1,600 HK$ 20,640
9 lots 1,800 HK$ 23,220
10 lots 2,000 HK$ 25,800
15 lots 3,000 HK$ 38,700
20 lots 4,000 HK$ 51,600
25 lots 5,000 HK$ 64,500
30 lots 6,000 HK$ 77,400
35 lots 7,000 HK$ 90,300
40 lots 8,000 HK$ 103,200
45 lots 9,000 HK$ 116,100
50 lots 10,000 HK$ 129,000
100 lots 20,000 HK$ 258,000
150 lots 30,000 HK$ 387,000
200 lots 40,000 HK$ 516,000
250 lots 50,000 HK$ 645,000
300 lots 60,000 HK$ 774,000
350 lots 70,000 HK$ 903,000
400 lots 80,000 HK$ 1,032,000
450 lots 90,000 HK$ 1,161,000
500 lots 100,000 HK$ 1,290,000
1,000 lots 200,000 HK$ 2,580,000
1,500 lots 300,000 HK$ 3,870,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 400,000 HK$ 5,160,000
2,500 lots 500,000 HK$ 6,450,000
3,000 lots 600,000 HK$ 7,740,000
3,500 lots 700,000 HK$ 9,030,000
4,000 lots 800,000 HK$ 10,320,000
4,500 lots 900,000 HK$ 11,610,000
5,000 lots 1,000,000 HK$ 12,900,000
6,000 lots 1,200,000 HK$ 15,480,000
7,000 lots 1,400,000 HK$ 18,060,000
8,361 lots 1,672,200 HK$ 21,571,380

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 9.95B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap met, expected inclusion ~2027-03-08

Valuation & Financials

Market Cap (at Offer Price)HK$ 5,075,409,540
H-Share Market Cap (at Offer Price)HK$ 3,823,067,800
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot applicable (loss-making)
Profit/Loss StatusNet loss RMB 258.7 million
Period-End Cash BalanceRMB 132.19 million
Listing Expenses~HK$ 54,400,000
Listing Expenses / Funds Raised~11.5%
Total Pre-IPO InvestmentRMB 994.38 million
First Day CloseHK$ 33.28
First Day OpenHK$ 33.0
First Day Change157.98%
First Day Volume8992780.0
First Day Turnover297614000.0
Use of Proceeds
1、約63.6%或266.9百萬港元將分配至核心產品的開發及國內外注冊; 2、約18.1%或76.4百萬港元將用于其他在研疫苗的開發和注冊; 3、約8.4%或35.4百萬港元將分配至提升生產及商業化能力; 4、約4.9%或20.8百萬港元將分配至技術平臺的開發、升級及運營; 5、約5.0%或21.0百萬港元將分配至營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
中信证券(香港)有限公司 CE AAK249 招银国际融资有限公司 CE AVM940
Overall Coordinators (2)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940
Joint Global Coordinators (2)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940
Joint Bookrunners (7)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 Livermore Holdings Limited CE BJN764 Funde Securities Limited CE BHT984 ARISTO SECURITIES LIMITED CE BDH167 中银国际亚洲有限公司 CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Joint Lead Managers (7)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 Livermore Holdings Limited CE BJN764 Funde Securities Limited CE BHT984 ARISTO SECURITIES LIMITED CE BDH167 中银国际亚洲有限公司 CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Capital Market Intermediaries (7)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 Livermore Holdings Limited CE BJN764 Funde Securities Limited CE BHT984 ARISTO SECURITIES LIMITED CE BDH167 中银国际亚洲有限公司 CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Stabilizing Manager (1)
中信证券(香港)有限公司 CE AAK249

Service Providers

RoleInstitution
Legal Advisor to Company 年利达律师行
北京国枫律师事务所
北京市嘉源律师事务所
Legal Advisor to Sponsors/Underwriters 高伟绅律师行
通商律师事务所
Auditor and Reporting Accountant 德勤•关黄陈方会计师行
Industry Advisor 弗若斯特沙利文(北京)咨询有限公司上海分公司
Receiving Banks 中国银行(香港)有限公司

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 嘉兴鑫扬及华泰资本投资(与华泰背对背总回报掉期及华泰客户总回报掉期有关) 13,000,000 USD 7,113,600 21.30% 1.80% 6 months 2026-02-11

Directors & Management

PositionChinese nameEnglish Name
ChairmanMr. An YoucaiMr. An Youcai
Company SecretaryMs. Zhang YangyangMs. Zhang Yangyang
Executive Director安有才An Youcai
Non-Executive Director程千文Cheng Qianwen
Independent Non-Executive Director李向明Li Xiangming
Executive Director李润香Li Runxiang
Non-Executive Director于建林Yu Jianlin
Independent Non-Executive Director李晓青Li Xiaoqing
Executive Director何一鸣He Yiming
Non-Executive Director杜沐Du Mu
Independent Non-Executive Director陈乘贝Chen Chengbei
Independent Non-Executive Director封浩Feng Hao
Independent Non-Executive Director王曙光Wang Shuguang
Independent Non-Executive Director王威Wang Wei

Major Shareholders

Major Shareholders & HoldingsThe Controlling Shareholder Group comprises the Persons Acting in Concert Group (Mr. An, 江蘇糶宇 and Mr. He) and the Employee Shareholding Platforms (泰州慧達, 泰州慧融, 泰州慧隆, 泰州慧新, 泰州慧寧 and 泰州慧嘉), which collectively hold approximately 45.55% of the Shares. Immediately after the completion of the Global Offering, the Controlling Shareholder Group will collectively hold approximately 41.68% of the Shares (assuming the Over-Allotment Option is not exercised).
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

With an offer price of HK$12.9 and an entry threshold of HK$2,580, the IPO drew an extraordinary oversubscription ratio of 4,007.64 times, signaling intense retail demand for this 18A biotech listing. The overall hit rate was a mere 9.87%, meaning only about one in ten applications succeeded, highlighting the fierce competition. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

The tier distribution shows a stark inefficiency at the boundary: 甲尾 applicants, applying for 300,000 shares, could expect just 0.24 lots, while 乙头 subscribers with 400,000 shares saw an expected 0.6 lots—more than double the lots for only a 33% increase in shares. This indicates a disproportionately large jump in allocation probability when crossing into the B tier. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Successful applicants were predominantly male (61.3%) with an average age of 42.8, and a striking 69.7% hailed from mainland China, underscoring the strong cross-border demand for Hong Kong biotech IPOs. Hong Kong residents accounted for just 29.5% of the allotment, pointing to a heavily mainland-driven investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Ab&b Bio-Tech-B (02627) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect